Gastrointestinal Bleeding Treatment Market Trends

• Increasing incidence of gastrointestinal bleeding (GIB) is a significant driver of the market.
  
• Several factors such as rising aging population coupled with increasing prevalence of gastrointestinal disorders such as peptic ulcers, gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), as well as the growing use of NSAID’s is contribution to the increasing cases of GI tract bleeding.
  
• For instance, as per the National Institute of Health (NIH), peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5−10% in the general population.
  
• Additionally, lifestyle factors such as smoking, excessive alcohol consumption, and poor dietary habits also play a role in the development of GI bleeding.
  
• Thus, as the incidence of GI bleeding continues to rise, there is a growing need for effective treatments to manage this condition and its complications, driving the growth of the market.